-
Syntrix Wins U.S. Patent 10,046,002 – Method for Treating Cancer Using Chemokine Antagonists
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
1 -
World Health Organization’s INN Approves “Desmetramadol” as Generic Name for Omnitram
-Syntrix today announced that the World Health Organization’s International Nonproprietary Name (INN) group have accepted the proposed generic name “Desmetramadol”…
-
Syntrix Joins National Cancer Institute (NCI) Formulary to Help Expedite Cancer Clinical Trials – Collaboration Will Support Vice President Biden’s Cancer Moonshot Program
-Syntrix today announced their participation in the NCI Formulary, a public-private partnership between the National Cancer Institute (NCI), part of…
-
Syntrix Doses First Subject with Omnitram to Confirm Pain Relief in Patients for Whom Tramadol is Ineffective
-Large patient populations treated with dangerous Schedule II opioids are expected to benefit from Omnitram, a safer alternative without metabolic…
-
Syntrix Wins Three U.S. Patents for Omnitram – 9,717,700; 9,717,701; 9,808,432
-Congratulations to Syntrix scientists on their latest issued patents at the United States Patent and Trademark Office. ‘701 Abstract: Disclosed…
-
Syntrix Wins U.S. Patent 9,707,248 – Use of Thiopyrimidinecarboxamide for Treating Cancer
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
-
Syntrix to Collaborate with NCI to Study SX-682 – Cooperative Research and Development Agreement (CRADA) Assesses SX-682 Alone and In Various Combinations
-Syntrix today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute…
-
Syntrix Receives $2.3M Grant to Conduct a Phase 1/2 Clinical Trial Evaluating SX-682 Alone and with Pembrolizumab in Metastatic Melanoma
-Syntrix announced today the award of a $2.3 million grant from the National Cancer Institute (NCI) of the National Institutes…
-
Study Published in Nature Provides Path for New Immunotherapy to Prostate Cancer Using SX-682 – Results Underpin Clinical Trial of SX-682 With Anti-PD1 and Anti-CTLA4 Combination
-Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, is made “hot” by the addition of SX-682,…
-
Syntrix Wins U.S. Patent 9,480,694 – Thiopyrimidinecarboxamide for Use in Treating Pulmonary Disease
-Congratulations to Syntrix scientists on their latest issued patent at the United States Patent and Trademark Office. Inventors: Maeda, Dean…
News
Syntrix Pharmaceuticals > News